Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players Published BY Marketresearchreports.biz

Japan Pharmaceutical Market Outlook Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Japan Pharmaceutical Market Outlook Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005 to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%.

To Buy a Copy Of This Report:    http://www.marketresearchreports.biz/analysis-details/japan-pharmaceutical-market-outlook-deregulation-and-more-efficient-new-drug-approval-process-attract-foreign-investment-and-improve-the-competitiveness-of-japanese-players

Growth of the domestic pharmaceutical industry has recently been hampered by biennial drug price reductions, which are expected to continue as the government attempts to cut healthcare expenditure. Price reviews are also constrained by a national health budget, which limits the increase of drug prices. In addition, the gradual increase in market share and competition from generics has depressed market value and will continue to do so as government policy promotes their use.

However, easing of regulatory guidelines, an aging population and a strong product pipeline will provide a strong impetus for growth in the pharmaceutical industry. Although the increasing market share of generics may dampen market value, this represents a great deal of opportunity for generic manufacturers.

Historically, the Japanese pharmaceutical market has favored domestic companies. However, since the 1990s, deregulation has promoted investment from abroad and increased the presence of foreign firms.

To Read The Complete Report with : http://www.marketresearchreports.biz/analysis/167326

Scope

• The report assesses characteristics of the Japanese pharmaceutical market, detailing recent regulatory changes, supply chain and competitive landscape. It also draws on macroeconomic and demographic factors and the implications on healthcare policy.
• A macroeconomic analysis of Japan, focusing on key economic parameters such as Gross Domestic Product (GDP), inflation and unemployment. The implications of the global financial crisis in 2008 and natural disaster in 2011 are considered.
• The changing demographic landscape and implications on health economics and policy-making.
• The industry characteristics section presents an overview of pricing policies, the regulatory landscape, new drug approval process and pharmaceutical supply chain in Japan. Notable changes that have occurred over recent years, in an attempt to improve the regulatory system and reduce drug review times, are highlighted.
• The report then analyzes the competitive landscape in Japan, including the major domestic companies and M&A. The discussed regulatory reforms and cooperation between government and industry have improved the international competitiveness of Japan’s pharmaceutical market. Coupled with a number of mergers, the industry now consists of well-known multinationals. The competitive landscape section confirms the top five Japanese pharmaceutical companies by revenue, according to GBI Research data.
• The report concludes by providing an overview of the drivers and barriers currently facing the Japanese pharmaceutical industry.

Reasons to buy

• Primarily, the report will allow clients to gain a strong understanding of the economic and healthcare challenges facing Japan. 
• In addition, the report will assist in identifying opportunities within Japan’s pharmaceutical market, including:
• Potential for market growth A number of factors could provide strong potential for sales growth in the Japanese pharmaceutical market. Examples include the world leading life expectancy and associated increase in lifestyle diseases, and government initiatives to prevent such diseases, which provides opportunities for healthcare and pharmaceutical companies, who often carry out the work.
• The report provides a source of information covering Japan’s regulatory landscape, and importantly, recent deregulation, to help identify the reasons Japan has become an attractive market for big pharma.
• The report will provide new market entrants with a comprehensive overview of the leading Japanese pharmaceutical companies, and the specific therapeutic indications they are currently targeting. 
• Overall, allowing clients to determine whether the Japanese pharmaceutical market will provide them with commercially viable opportunities for growth.

Latest  Report:

Remote Patient Monitoring Market to 2019 - Potential to Reduce Healthcare Cost Burden and Improve Quality of Care to Drive Future Growth: http://www.marketresearchreports.biz/analysis/165977

GBI Research’s report “Remote Patient Monitoring Market to 2019 – Potential to Reduce Healthcare Cost Burden and Improve Quality of Care to Drive Future Growth” looks at the market, competitive landscape, and trends for the two remote patient monitoring market segments: implantable remote patient monitoring and external remote patient monitoring. The report provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape and gives a detailed analysis of each segment’s pipeline products, as well as details of important M&A deals.